- Home
- Products
- Customized FluoroAb™
- ERBB2
- Anti-ERBB2 MAb (Clone 31)-iFluor® 405 Succinimidyl Ester
Anti-ERBB2 MAb (Clone 31)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2441)
- TARGET
- ANTIBODY
- DYE
- Name
- ERBB2
- Alternative Names
- ERBB2; v-erb-b2 erythroblastic leukemia viral oncogene homolog 2; neuro/glioblastoma derived oncogene homolog (avian); NGL; v erb b2 avian erythroblastic leukemia viral oncogene homolog 2 (neuro/glioblastoma derived oncogene homolog); receptor tyrosine-prEGF receptor family members to form a heterodimer; stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways; such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported; with the most common allele; Ile654/Ile655; shown he
- Overview
- This gene encodes a member of the epidermal growth factor (EGF) receptor family of receptor tyrosine kinases. This protein has no ligand binding domain of its own and therefore cannot bind growth factors. However, it does bind tightly to other ligand-bound EGF receptor family members to form a heterodimer, stabilizing ligand binding and enhancing kinase-mediated activation of downstream signalling pathways, such as those involving mitogen-activated protein kinase and phosphatidylinositol-3 kinase. Allelic variations at amino acid positions 654 and 655 of isoform a (positions 624 and 625 of isoform b) have been reported, with the most common allele, Ile654/Ile655, shown here. Amplification and/or overexpression of this gene has been reported in numerous cancers, including breast and ovarian tumors. Alternative splicing results in several additional transcript variants, some encoding different isoforms and others that have not been fully characterized.
- Overview
- Chimeric Anti-ERBB2 IgG4-kappa (Clone 31)
- Species Reactivity
- Human
- Name
- iFluor® 405 Succinimidyl Ester
- Color
- Blue
- Excitation⁄Emission (nm)
- 403/427
- Detection method
- Fluorescent
Published Data
+ Submit Publications
Scientific Resources
Customer Reviews and FAQs
There are currently no Customer reviews or questions for WJY0-LS2441. Click the button above to contact us or submit your feedback about this product.
Quick Links
Other Products
Same Target
| CAT# | Product Name | Linker | Payload |
| ADC-W-1116 | Anti-ERBB2 (Pertuzumab)-MC-Vc-PAB-SN38 ADC | MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) | SN-38 (7-ethyl-10-hydroxycamptothecin) |
| ADC-W-582 | Anti-ERBB2-SMCC-DM1 ADC | SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) | DM1 (N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2595 | Anti-ERBB2 (Trastuzumab)-SPDB-DM4 ADC | SPDB (N-succinimidyl-4-(2-pyridyldithio)butyrate) | DM4 (N2'-Deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)maytansine) |
| ADC-W-116 | Anti-ERBB2 (Trastuzumab)-Gly5-modified DM1 ADC | C-terminal GS (glycine-serine) linker | Gly5-modified DM1 (Gly5-modified N2’-Deacetyl-N2’-(3-mercapto-1-oxopropyl)maytansine) |
| ADC-W-2597 | Anti-ERBB2 (Trastuzumab)-MC-Vc-PAB-DMEA-(PEG2)-duocarmycin SA ADC | MC-Vc-PAB-DMEA-(PEG2) | duocarmycin SA |
For Research Use Only. NOT FOR CLINICAL USE.
Related Products
- Anti-AOC3 MAb (Clone 6)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS4157)
- Anti-ERBB3 MAb (Clone 4)-iFluor® 405 Succinimidyl Ester (CAT#: WJY0-LS2326)
- Anti-HGF MAb (Clone 2)-iFluor® 430 Succinimidyl Ester (CAT#: WJY0-LS3678)
- Anti-CD74 MAb (Clone 3)-iFluor® 350 Succinimidyl Ester (CAT#: WJY0-LS245)
- Anti-ACVR2B MAb (Clone 4)-iFluor® 514 Succinimidyl Ester (CAT#: WJY0-LS11837)
- Futuximab-iFluor 405 (CAT#: ADC-FL-1172)
- Ziralimumab-Coumarin (CAT#: ADC-FL-229)
- Anti-MET MAb (Clone 12)-iFluor® 532 Succinimidyl Ester (CAT#: WJY0-LS13709)
- Anti-FUT3 MAb (Clone 2)-iFluor® 440 Succinimidyl Ester (CAT#: WJY0-LS5049)
- Daratumumab-iFluor 568 (CAT#: ADC-FL-529)
Online Inquiry
Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.